All Stories

  1. Approach to diagnosing and managing granulomatous-lymphocytic interstitial lung disease
  2. Transcriptomic Profiling of Peripheral B Cells in Antibody Positive Sjogren’s Patients Reveals Interferon Signature
  3. Alternative assays for identifying the inciting antigen in hypersensitivity pneumonitis
  4. Rationale and design of the prognostic transcriptomic signature in fibrotic hypersensitivity pneumonitis (PREDICT) study
  5. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety
  6. Uncovering the Risk of Inhalational Exposures Across Interstitial Lung Diseases
  7. Prognostic accuracy of a peripheral blood transcriptome signature in chronic hypersensitivity pneumonitis
  8. Diagnosis and Evaluation of Hypersensitivity Pneumonitis: CHEST Guideline and Expert Panel Report − Executive Summary
  9. Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
  10. Exposure Assessment Tools for Hypersensitivity Pneumonitis. An Official American Thoracic Society Workshop Report
  11. In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs
  12. Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
  13. Age-associated B Cells Appear in Patients with Granulomatous Lung Diseases
  14. Soldiering on the Job When Ill: Productivity Costs in Connective Tissue Disease–associated Interstitial Lung Disease
  15. IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis
  16. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
  17. Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA
  18. Clinical Decision-Making in Hypersensitivity Pneumonitis: Diagnosis and Management
  19. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
  20. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
  21. Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis-Related Mortality in the United States, 1999 to 2017
  22. Reply to Hall et al.: Hypersensitivity Pneumonitis Mortality by Industry and Occupation
  23. Increasing Hypersensitivity Pneumonitis–related Mortality in the United States from 1988 to 2016
  24. The Role of Computed Tomography Honeycombing in Profiling Disease Progression in Chronic Interstitial Lung Disease
  25. Changing trends in age-adjusted pulmonary fibrosis mortality in the USA: a joinpoint regression analysis
  26. United States trends in mortality rates for primary immunodeficiency diseases
  27. IPF Look-Alikes
  28. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
  29. Diagnostic Decision-Making in Hypersensitivity Pneumonitis: Toward a Consensus Statement
  30. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
  31. Epidemiology of Hypersensitivity Pneumonitis among an Insured Population in the United States: A Claims-based Cohort Analysis
  32. An educational initiative to improve the team-based care of patients with idiopathic pulmonary fibrosis
  33. Presence of Air Trapping and Mosaic Attenuation on Chest Computed Tomography Predicts Survival in Chronic Hypersensitivity Pneumonitis
  34. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis
  35. Refining the Burden of Idiopathic Pulmonary Fibrosis: The Cocktail Party Effect
  36. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival
  37. Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease
  38. Current Approach to Diagnosis and Management of Pulmonary Eosinophilic Syndromes: Eosinophilic Pneumonias, Eosinophilic Granulomatosis with Polyangiitis, and Hypereosinophilic Syndrome
  39. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
  40. Inflammatory Leukocyte Phenotypes Correlate with Disease Progression in Idiopathic Pulmonary Fibrosis
  41. Fibrotic hypersensitivity pneumonitis
  42. Pulmonary Function and Survival in Idiopathic vs Secondary Usual Interstitial Pneumonia
  43. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study
  44. Nonasthmatic Eosinophilic Bronchitis
  45. Bronchiectasis
  46. Eosinophilic Lung Diseases
  47. Identifying an Inciting Antigen Is Associated With Improved Survival in Patients With Chronic Hypersensitivity Pneumonitis
  48. FEV1 over time in patients with connective tissue disease-related bronchiolitis
  49. Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease
  50. Granulomatous Lymphocytic Interstitial Lung Disease
  51. Peeling away the layers of the volume-outcome effect and harvesting hidden connections*
  52. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease
  53. Obstructive sleep apnea does not promote esophageal reflux in fibrosing interstitial lung disease
  54. Rheumatoid Arthritis and Pneumoconiosis
  55. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death
  56. Air hunger, unwelcome guests, clogged pipes and idiopathic inflammatory myositis: Can we do better?
  57. Interpretation of airway pressure waveforms
  58. Eosinophilic Lung Diseases
  59. Increased Risk of Pulmonary Embolism Among US Decedents With Sarcoidosis From 1988 to 2007
  60. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease
  61. Derivation and Diagnostic Accuracy of the Surgical Lung Injury Prediction Model
  62. Sarcoidosis-related Mortality in the United States from 1988 to 2007
  63. Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
  64. Rheumatoid Arthritis–Interstitial Lung Disease–associated Mortality
  65. Long-Term Survival and Quality of Life After Transfusion-Associated Pulmonary Edema in Critically III Medical Patients
  66. Severity of Illness and Outcome in Patients With End-Stage Idiopathic Pulmonary Fibrosis Requiring Mechanical Ventilation: Response
  67. Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis
  68. Outcome of critically ill patients with influenza virus infection
  69. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia
  70. Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis
  71. Intraoperative ventilator settings and acute lung injury after elective surgery: a nested case control study
  72. Respiratory Monitoring
  73. Interpretation of airway pressure waveforms
  74. Ventilator Settings and Outcome of Respiratory Failure in Chronic Interstitial Lung Disease
  75. The Practice of Platelet Transfusion in the Intensive Care Unit
  76. The addition of decision support into computerized physician order entry reduces red blood cell transfusion resource utilization in the intensive care unit
  77. Nonfamilial hemophagocytic lymphohistiocytosis
  78. Post-thoracentesis trapped lung
  79. Acute pancreatitis due to hereditary angioedema
  80. Transfusion‐related acute lung injury and pulmonary edema in critically ill patients: a retrospective study
  81. Intraoperative Tidal Volume as a Risk Factor for Respiratory Failure after Pneumonectomy
  82. A case of hydrocortisone desensitization in a patient with radiocontrast-induced anaphylactoid reaction and corticosteroid allergy
  83. Interpretation of airway pressure waveforms
  84. Sepsis during pregnancy
  85. Interpretation of airway pressure waveforms